| Literature DB >> 26991939 |
Lena Shukla1, Laura A Ajram2, Malcolm Begg2, Brian Evans1, Rebecca H Graves3, Simon T Hodgson1, Sean M Lynn4, Afjal H Miah1, Jonathan M Percy5, Panayiotis A Procopiou6, Stephen A Richards4, Robert J Slack2.
Abstract
A number of potent 2,8-diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine CCR4 antagonists binding to the extracellular allosteric site were synthesised. (R)-N-(2,4-Dichlorobenzyl)-2-(2-(pyrrolidin-2-ylmethyl)-2,8-diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine (R)-(18a) has high affinity in both the [(125)I]-TARC binding assay with a pKi of 8.8, and the [(35)S]-GTPγS functional assay with a pIC50 of 8.1, and high activity in the human whole blood actin polymerisation assay (pA2 = 6.7). The most potent antagonists were also investigated for their ability to induce endocytosis of CCR4 and were found to internalise about 60% of the cell surface receptors, a property which is not commonly shared by small molecule antagonists of chemokine receptors.Entities:
Keywords: CCR4 antagonist; Endocytosis; Receptor internalisation
Mesh:
Substances:
Year: 2016 PMID: 26991939 DOI: 10.1016/j.ejmech.2016.02.058
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514